ABACUS MEDICINE A/S: Financial statements 2022
CVR: 28111576
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ABACUS MEDICINE A/S (CVR 28111576) has filed annual accounts for 2022. In 2022, the company reported revenue of EUR 1,023,978,000 and a net result of EUR 5,819,000 compared with EUR 415,000 the year before. That is an increase of 8.8% compared with the year before. The profit margin was 0.6%. Equity in the 2022 report amounted to EUR 60,991,000. The solvency ratio was 26.2%.
- Revenue
- EUR 1,023,978,000
- Profit/Loss
- EUR 5,819,000
- Equity
- EUR 60,991,000
- Total Assets
- EUR 232,976,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 1B EUR | - | 5.8M EUR | 61M EUR | - |
| 2021 | 940.7M EUR | - | 415K EUR | 54.6M EUR | - |
| 2020 | 663.5M EUR | - | 433K EUR | 53M EUR | - |
| 2019 | 421.4M EUR | - | 829K EUR | 51.6M EUR | - |
| 2018 | 332.3M EUR | 40.8M EUR | 5.4M EUR | 14.4M EUR | - |
Official annual report
Keep an eye on ABACUS MEDICINE A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ABACUS MEDICINE A/S has published its annual report for 2021. Revenue came to DKK 940,740,000, and the net result was DKK 415,000.
About ABACUS MEDICINE A/S
ABACUS MEDICINE A/S is a Danish company of the type Aktieselskab based in København V, founded in 2004. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ABACUS MEDICINE ApS. The management consists of Flemming Wagner. The board consists of Jens Albert Harsaae (chair), Alette Margaretha Verbeek, Anders Kunze Bønding and Flemming Wagner. The company is owned by Wagner Family Holding ApS and CHR. AUGUSTINUS FABRIKKER AKTIESELSKAB. The company has 388 employees (2026). In 2025, the company reported revenue of EUR 1,817,637,000 and a net result of EUR 7,779,000 compared with EUR 17,621,000 the year before. Equity in the 2025 report amounted to EUR 98,523,000.